Mar 5, 2026 11:31AM
Mar 5, 2026 07:00AM
Jan 29, 2026 05:54PM
Jan 29, 2026 05:54PM
Jan 27, 2026 09:25PM
Jan 27, 2026 09:25PM
Jan 27, 2026 06:32AM Altimmune (ALT) PT Lowered to $22 at Evercore ISI
Jan 5, 2026 07:31AM
Jan 5, 2026 07:30AM
Dec 19, 2025 06:30AM
Dec 19, 2025 06:30AM
Dec 1, 2025 07:31AM
Dec 1, 2025 07:30AM
Nov 12, 2025 04:47AM Altimmune's (ALT) on Leading Edge of Pemvidutide Development - Citizens
Nov 11, 2025 08:52AM
Nov 11, 2025 08:51AM
Nov 7, 2025 08:06AM
Nov 7, 2025 08:05AM
Nov 6, 2025 07:00AM
Nov 3, 2025 07:30AM
Nov 3, 2025 07:30AM Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder
Oct 20, 2025 07:30AM
Sep 29, 2025 07:30AM
Sep 29, 2025 07:30AM
Aug 19, 2025 07:30AM
Aug 19, 2025 07:30AM
Aug 12, 2025 07:00AM
Aug 11, 2025 07:30AM Altimmune names Jerry Durso as board chairman
Aug 11, 2025 07:30AM
Jul 9, 2025 07:30AM
Jul 9, 2025 07:30AM
Jun 26, 2025 07:02AM
Jun 26, 2025 07:00AM
Jun 25, 2025 07:12PM
Jun 13, 2025 07:30AM Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association’s Scientific Sessions
May 19, 2025 07:31AM
May 19, 2025 07:30AM
May 13, 2025 07:00AM
May 8, 2025 07:30AM
May 1, 2025 07:30AM
Apr 4, 2025 06:42AM
Mar 4, 2025 06:43AM H.C. Wainwright Reiterates Buy Rating on Altimmune (ALT)
Feb 27, 2025 07:00AM
Dec 19, 2024 07:30AM
Dec 19, 2024 07:30AM
Nov 15, 2024 11:01AM
Nov 15, 2024 11:00AM
Nov 12, 2024 07:00AM
Nov 7, 2024 07:30AM Altimmune (ALT) Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide
Nov 7, 2024 07:30AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All